Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains
Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof. In some examples, the alkaloid ergotamine contains dihydroergotamine, such as dihydroergotamine mesylate and the hydrofluorocarbon fluid vehicle contains HFA 134a, HFA 227ea, or mixtures thereof.
대표청구항▼
1. An aerosol formulation comprised in an aerosol canister, the aerosol formulation comprising: a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm, suspended in a hydrofluorocarbon fluid vehicle at a concentration within a r
1. An aerosol formulation comprised in an aerosol canister, the aerosol formulation comprising: a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 μm, suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v, wherein the aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle, and the particulate active substance is an ergot alkaloid, or a pharmaceutically acceptable salt analogue, or derivative thereof. 2. The aerosol formulation of claim 1, wherein the ergot alkaloid is an ergotamine or a pharmaceutically acceptable salt, analogue, or derivative thereof. 3. The aerosol formulation of claim 2, wherein the ergotamine is dihydroergotamine. 4. The aerosol formulation of claim 1, wherein the hydrofluorocarbon fluid vehicle comprises 1, 1, 1, 2-tetrafluoroethane (HFA 134a), 1, 1, 1, 2, 3, 3, 3- heptafluoropropane (HFA 227ea), or a mixture thereof. 5. The aerosol formulation of claim 1, exhibiting a flocculation volume of about 85% or greater about 5 minutes after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. 6. The aerosol formulation of claim 5, exhibiting a flocculation volume of about 85% or greater about 10 minutes after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. 7. The aerosol formulation composition of claim 6, exhibiting a flocculation volume of about 100% about 10 minutes after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. 8. The aerosol formulation of claim 1, wherein the particulate active substance is suspended in the hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 3% w/v. 9. The aerosol formulation of claim 8, wherein the particulate active substance is suspended in the hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.5% w/v to about 1.5% w/v. 10. The aerosol formulation of claim 1, wherein the mass median aerodynamic diameter is about 5 μm or less. 11. The aerosol formulation of claim 10, wherein the mass median aerodynamic diameter is about 3 μm or less. 12. The aerosol formulation of claim 1, wherein the particulate active substance is in a crystalline form. 13. The aerosol formulation of claim 12, wherein the crystalline form is significantly longer in one dimension than in at least one other dimension. 14. An aerosol formulation comprised in an aerosol canister, the aerosol formulation comprising: a particulate active substance of non-micronized, solid particles having a mass median diameter of less than 15 μm, suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v, wherein the aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle, and the particulate active substance is an ergot alkaloid, or a pharmaceutically acceptable salt, analogue, or derivative thereof. 15. The aerosol formulation of claim 14, wherein the ergot alkaloid is an ergotamine, or a pharmaceutically acceptable salt, analogue, or derivative thereof. 16. The aerosol formulation of claim 15, wherein the ergotamine is dihydroergotamine. 17. The aerosol formulation of claim 14, wherein the hydrofluorocarbon fluid vehicle comprises 1, 1, 1, 2-tetrafluoroethane (HFA 134a), 1, 1, 1, 2, 3, 3, 3- heptafluoropropane (HFA 227ea), or a mixture thereof. 18. The aerosol formulation of claim 17, wherein the mass median diameter is about 3 μm or less. 19. The aerosol formulation of claim 14, exhibiting a flocculation volume of about 85% or greater about 10 minutes after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. 20. The aerosol formulation of claim 14, wherein the particulate active substance is suspended in the hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 3% w/v. 21. The aerosol formulation of claim 3, wherein the dihydroergotamine is dihydroergotamine mesylate. 22. The aerosol formulation of claim 16, wherein the dihydroergotamine is dihydroergotamine mesylate. 23. The aerosol formulation of claim 1, comprising less than 0.01% w/w surfactant. 24. The aerosol formulation of claim 1, wherein the aerosol canister is suitable for use in a metered dose inhaler.
연구과제 타임라인
LOADING...
LOADING...
LOADING...
LOADING...
LOADING...
이 특허에 인용된 특허 (174)
Baker Jeffrey C. ; Hanquier Jose M., Acylated Insulin Analogs.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Edwards David A. ; Caponetti Giovanni,ITX ; Hrkach Jeffrey S. ; Lotan Noah,ILX ; Hanes Justin ; Ben-Jebria Abdell Aziz ; Langer Robert S., Aerodynamically light particles for pulmonary drug delivery.
Taylor Anthony James,GBX ; Neale Philip John,GBX, Aerosol formulation containing beclomethasone dipropionate and 1,1,1,2,3,3,3-heptafluoro-n-propane as propellant.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Aerosol formulation containing particulate formoterol, propellant and polar cosolvent.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Aerosol formulations containing P134A and/or P227 and particulate medicament.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Aerosol formulations containing propellant 134a and fluticasone propionate.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Aerosol formulations containing salmeterol xinafoate, an anticholinergic agent and tetrafluoroethane.
Evans Richard M. (Westwood MA) Farr Stephen J. (Llandaf GB7), Aerosol formulations including proteins and peptides solubilized in reverse micelles and process for making the aerosol.
Greenleaf David J. (Loughborough GB2) Howarth Peter H. (Beeston GB2) Jinks Philip A. (Mountsorrel GB2), Aerosol valve with a surfactant impregnated valve seal.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Aerosols containing salmeterol xinafoate and an anticholinergic medicament.
Phillipps Gordon H. (Wembley GB2) Bain Brian M. (Chalfont St. Peter GB2) Steeples Ian P. (Ruislip Manor GB2) Williamson Christopher (Cobham GB2), Androstane carbothioates.
Bartlett Philip L. (Wilmington DE) Bivens Donald B. (Kennett Square PA) Lunger Brooks S. (Coatesville PA) Yokozeki Akimichi (Greenville DE), Azeotropic and azeotrope-like compositions of 1,1,2,2-tetrafluoroethane.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann,GB3 ; Taylor Anthony James,GB3 ; Wyatt David Andrew,GB3, Canister containing aerosol formulations containing P134a and particulate medicaments.
Akehurst Rachel Ann (Ware GB3) Taylor Anthony James (Ware GB3) Wyatt David Andrew (Ware GB3), Canisters containing aerosol formulations containing P134a and fluticasone propionate.
Wang Yu-chang J. (Los Altos CA) Lee William A. (Los Altos CA) Narog Blair (Palo Alto CA), Composition and method for administration of pharmaceutically active substances.
Crowley ; Jr. William F. (Newtonville MA), Continuous delivery of luteinizing hormone releasing hormone compositions in combination with sex steroid delivery for u.
Murthy Andiappan K. S. (Convent Station NJ) Bekker Alex Y. (Teaneck NJ) Patel Kundanbhai M. (Landing NJ), Deposition of thin films using supercritical fluids.
Andersson Jan A. R. (S. Sandby SEX) Nilsson Nils G. (Lund SEX) Fagerstrm Per-Olof S. (Bjrred SEX) Wendel Thomas M. (Genarp SEX), Device in connection with an inhaler.
Jinks Philip A. (Mountsorrel GB3) Bell Alexander (Chilwell GB3) Fischer Franz X. (Riehen CHX), Drug-containing chlorofluorocarbon aerosol propellent formulations.
Byron Peter R. (Richmond) Dalby Richard N. (Richmond VA), Formulation for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Dalby Richard N. (Richmond) Byron Peter R. (Richmond VA), Formulations for delivery of beclomethasone diproprionate by metered dose inhalers containing no chlorofluorocarbon prop.
Byron Peter R. (Richmond VA) Dalby Richard N. (Richmond VA), Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content.
Badger Alison M. (Bryn Mawr PA) Cheeseman Elaine N. (Phoenixville PA) DiMartino Michael J. (Philadelphia PA) Dorman James W. (West Chester PA) Mirabelli Christopher K. (Exton PA) Picker Donald H. (Me, Immunomodulatory azaspiranes.
Byron Peter R. (Richmond VA) Blondino Frank E. (Richmond VA), Metered dose inhaler fomulations which include the ozone-friendly propellant HFC 134a and a pharmaceutically acceptable.
Hastings Donald R. (Elyria OH) Hendricks John A. (Vickery OH), Method and apparatus for spraying a liquid coating containing supercritical fluid or liquified gas.
Fischer Wilfried (Burscheid DEX) Mller Bernd W. (Flintbek DEX), Method and apparatus for the manufacture of a product having a substance embedded in a carrier.
Greenleaf David J. (Loughborough GB3) Purewal Tarlochan S. (Leamington Spa GB3) Jinks Philip A. (Mount Sorrel GB3), Method for preparing medicinal aerosol formulation containing coated medicament.
Rouanet Stephane Fabrice ; McGovern William Edward ; Cao Wanging ; Moses John M. ; Carrillo Angel L. ; Klotz Irving M., Method of forming particles using a supercritical fluid, aerogel particles formed thereby, and antiperspirants contain.
Evans Richard M. (Norwood MA) Farr Stephen J. (Cardiff GB7), Method of preparing medical aerosol formulations including drug dissolved in reverse micelles.
Gorissen Elke (Offenburg DEX) Biskup Heike (Langenfeld DEX) Schneider Hannelore (Dusseldorf DEX), Method of producing microscopic particles made of hydrolytically decomposable polymers and containing active substances.
Subramaniam Bala ; Saim Said ; Rajewski Roger A. ; Stella Valentino, Methods for particle micronization and nanonization by recrystallization from organic solutions sprayed into a compresse.
Fassberg Julianne (New York NY) Sequeira Joel A. (New York NY) Chaudry Imtiaz A. (North Caldwell NJ) Kopcha Michael (East Brunswick NJ), Non-chlorofluorocarbon aerosol formulations.
Sweval Mark A. (Lafayette IN) Register W. Douglas (West Lafayette IN) Robin Mark L. (West Lafayette IN) Iikubo Yuichi (West Lafayette IN), Ozone friendly sterilant mixture.
Akehurst Rachel Ann,GBX ; Taylor Anthony James,GBX ; Wyatt David Andrew,GBX, Pharmaceutical aerosol formulation containing a particulate medicament, a propellant and substantially free of a surfactant.
Boyes Robert N. (St. Albans AL GB2) Tice Thomas R. (Birmingham AL) Gilley Richard M. (Birmingham AL) Pledger Kenneth L. (Huntsville AL), Pharmaceutical formulations comprising microcapsules.
Byron Peter (Richmond VA) Blondino Frank (Richmond VA), Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formul.
Tanskanen Paavo T. (Kuopio FIX), Process for the preparation of a mixture of an anti-inflammatory steroid and a fluoro-chloro-hydrocarbon to be used as a.
Sarin Virender K. (Libertyville IL) Fox Jack L. (Lake Bluff IL) Gupta Shanker L. (Vernon Hills IL) Absolom Darryl R. (Columbus OH), Pulmonary surfactant protein fragments.
LaRoche Hans L. (Zrich CHX) Weber Markus (Zrich CHX) Zehnder Beat (Dbendorf CHX), Purification of salt-charged waste water by wet oxidation under super-critical conditions.
Manning Mark C. ; Randolph Theodore W. ; Shefter Eli ; Falk ; III Richard F., Solubilization of pharmaceutical substances in an organic solvent and preparation of pharmaceutical powders using the s.
Lee Chinsoo (Charleston WV) Hoy Kenneth L. (St. Albans WV) Donohue Marc D. (Ellicot City MD), Supercritical fluids as diluents in liquid spray application of coatings.
Liversidge Gary G. (West Chester PA) Cundy Kenneth C. (Pottstown PA) Bishop John F. (Rochester NY) Czekai David A. (Honeoye Falls NY), Surface modified drug nanoparticles.
Alkire Todd G. (Crystal MN) Sanftleben Ronald A. (Maple Grove MN) Schuehle Steven S. (Maple Grove MN), Taste masking microparticles for oral dosage forms.
Bckstrm Kjell G. E. (Lund SEX) Dahlbck Carl M. O. (Lund SEX) Edman Peter (Bjrred SEX) Johansson Ann C. B. (Lund SEX), Therapeutic preparation for inhalation.
Schultz Robert K. (Shoreview MN) Quessy Stephen N. (St. Paul MN), Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.